|
|
|
|
The UHC Expert Panel made specific recommendations for 53 off-label indications and the following general recommendations:(1)Usually IVIG is indicated only if standard approaches have failed,become intolerable,or are contraindicated;(2)IVIG products should be considered therapeutically equivalent and interchangeable;(3)interproduct pharmaceutical differences should be considered with the patient's clinical and physiological status when selecting an IVIG product;and(4)currently,IVIG manufacturers cannot guarantee freedom from viral contamination in the finished product. |
|